TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Sponsor: Senhwa Biosciences, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 52 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT04890613 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04890613 Rescue Dossier →